<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02858908</url>
  </required_header>
  <id_info>
    <org_study_id>AMO-02-MD-2-001</org_study_id>
    <secondary_id>2016-000067-16</secondary_id>
    <nct_id>NCT02858908</nct_id>
  </id_info>
  <brief_title>Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy</brief_title>
  <official_title>A Single-Blind, Phase 2 Study To Evaluate The Safety And Efficacy Of Tideglusib 400mg Or 1000mg For The Treatment Of Adolescent And Adult Congenital And Juvenile-Onset Myotonic Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AMO Pharma Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AMO Pharma Limited</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Tideglusib is safe and efficacious in the
      treatment of adolescents and adults with congenital and juvenile-onset Myotonic Dystrophy.
      The pharmacokinetics of tideglusib and its primary metabolite will also be investigated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is currently open for enrolment at the Newcastle Upon Tyne Hospitals NHS Trust for
      subjects aged between 16-45 years
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <primary_completion_date type="Actual">January 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs), including serious adverse events (SAEs), will be compared across two dose levels of tideglusib. SAEs and AEs will be examined throughout the study.</measure>
    <time_frame>14 weeks (baseline through end of study)</time_frame>
  </primary_outcome>
  <condition>Myotonic Dystrophy 1</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tideglusib</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adolescents or adults with diagnosis of congenital or juvenile-onset type 1 myotonic
             dystrophy (DM-1)

          -  Diagnosis must be genetically confirmed

          -  Subjects must be male or female aged 12 years to 45 years

          -  Subjects must have a Clinical Global Impression - Severity (CGI-S) score of 4 or
             greater at Screening and Run-in (V2)

          -  Subjects must be ambulatory and able to complete the 10 metre walk/run test (splints
             allowed)

          -  Subject's legally authorized representative (LAR) must provide written informed
             consent and there must be written consent or assent (as age applicable and
             developmentally appropriate) by the subject before any study-related procedures are
             conducted

        Exclusion Criteria:

          -  Non-ambulatory (full time) wheel chair user

          -  Receiving stimulant medication

          -  Receiving other medications/therapies not stable (changed) within 4 weeks prior to
             Run-in (V2)

          -  Medical illness or other concern which would cause investigator to conclude subjects
             will not be able to perform the study procedures or assessments or would confound
             interpretation of data obtained during assessment.

          -  Current enrolment in a clinical trial of an investigational drug or enrolment in a
             clinical trial of an investigational drug in the last 6 months

          -  Women of child bearing potential who are pregnant, lactating or not willing to use a
             protocol defined acceptable contraception method if sexually active and not surgically
             sterile.

          -  Gastrointestinal disease which may interfere with the absorption, distribution,
             metabolism or excretion of the study medication and impact the interpretability of the
             study results

          -  Current clinically significant (as determined by the investigator) cardiovascular,
             renal, hepatic, endocrine or respiratory disease

          -  Clinically significant heart disease (in the opinion of the investigator) or second or
             third degree heart block, atrial flutter, atrial fibrillation, ventricular
             arrhythmias, or is receiving medication for treatment of a cardiac arrhythmia

          -  A history of chronic liver disease with current out of range values for Alanine
             transaminase (ALT), clinically relevant hepatic steatosis or other clinical
             manifestations of ongoing liver disease

          -  A history of significant drug allergy (such as Steven-Johnson syndrome, anaphylaxis)

          -  A history of alcohol or substance use disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grainne Gorman, MB BCh BAO LRCP&amp;SI MRCP FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Neuroscience, Newcastle University.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Newcastle-upon-Tyne Hospitals NHS Trust</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <state>Tyne And Wear</state>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2016</study_first_submitted>
  <study_first_submitted_qc>August 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2016</study_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myotonic Dystrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

